SIREN : 393332846
BIOLUME is a French company founded 32 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in LOOS (59120), this company of category ETI shows in 2024 a revenue of 3.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2020 |
|---|---|---|---|
| Revenue | 3 331 012 € | 4 535 927 € | N/C |
| Net income | 277 202 € | 1 132 253 € | 14 936 € |
| EBITDA | 330 144 € | 493 259 € | N/C |
| Net margin | 8.3% | 25.0% | N/C |
In 2024, BIOLUME achieves revenue of 3.3 M€. Revenue is declining over the period 2023-2024 (CAGR: -26.6%). Significant drop of -27% vs 2023. After deducting consumption (1.1 M€), gross margin stands at 2.2 M€, i.e. a rate of 66%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 330 k€, representing 9.9% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 277 k€, i.e. 8.3% of revenue. This profit can be retained or distributed to shareholders.
3 331 012 €
2 211 511 €
330 144 €
307 034 €
277 202 €
9.9%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 8.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
0.0%
78.87%
8.913%
0.0
21.3%
In 2024, the debt ratio of BIOLUME (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of BIOLUME (78.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of BIOLUME (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 440.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.
440.207
0.01
In 2024, the liquidity ratio of BIOLUME (440.21) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIOLUME (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 92 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 81 days. The company must finance 11 days of gap between collections and payments. Inventory turnover is 63 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 145 days of revenue, i.e. 1.3 M€ to permanently finance.
1 345 129 €
92 j
81 j
63 j
145 j
Based on 57 transactions of similar company sales
(all years),
the value of BIOLUME is estimated at
814 673 €
(range 226 955€ - 1 582 376€).
With an EBITDA of 330 144€, the sector multiple of 2.5x is applied.
The price/revenue ratio is 0.23x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOLUME with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire
The revenue of BIOLUME in 2024 is 3.3 M€.
Yes, BIOLUME generated a net profit of 277 k€ in 2024.
The headquarters of BIOLUME is located in LOOS (59120), in the department Nord.
The tax return of BIOLUME is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOLUME operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.